Oragenics, Inc. (OGEN)

CIK 0001174940 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 —
Latest FY-2025 —
Q3-2025 —
Q2-2025 —
Q1-2025 —
FY-2024 —
Q3-2024 —
Q2-2024 —
Q1-2024 —
FY-2023 —
Q3-2023 —
Q2-2023 —
Q1-2022
Q3-2022
Q2-2022

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations
Condensed Consolidated Statements of Stockholders' Equity (deficit) (unaudited)
—
Consolidated Statements of Changes In Shareholders' (deficit) Equity
—
Consolidated Statements of Changes In Shareholders' Equity
Consolidated Statements of Cash Flows
Notes
Accounts Payable and Accrued Expenses
Acquisition of Concussion Assets
At The Market
—
Basis of Presentation
Basis of Presentation and Nature of Operations
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Income Taxes
—
Insider Trading Arrangements
Leases
—
License Agreements
—
License and Royalty Agreements
—
Net Loss Per Share
—
New Accounting Pronouncements
—
Organization
—
Pay Vs Performance Disclosure
Prepaid Expense Assets Current and Long-term
—
Prepaid Expense, Deposits, and Other Current Assets
—
Prepaid Expenses
—
Prepaid Expenses and Other Current Assets
—
Property and Equipment, Net
Retirement Plan
—
Shareholders Equity
Short-term Notes Payable
Significant Accounting Policies
Stock Compensation Plan
Stock-based Compensation
Subsequent Events
Warrants
—